Core Viewpoint - Silo Pharma, Inc. has successfully completed a public offering of 3,333,338 shares of common stock at a price of 2 million in gross proceeds for general working capital purposes [1][2]. Group 1: Offering Details - The public offering includes Series A-1 and Series A-2 warrants, each with an exercise price of $0.60 per share [1]. - Series A-1 Warrants are exercisable upon issuance and expire five years thereafter, while Series A-2 Warrants expire eighteen months after issuance [1]. - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [2]. Group 2: Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [5]. - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]. - Research is conducted in collaboration with leading universities and laboratories [5].
Silo Pharma Announces Closing of $2 Million Public Offering